Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review.
Journal
Mayo Clinic proceedings
ISSN: 1942-5546
Titre abrégé: Mayo Clin Proc
Pays: England
ID NLM: 0405543
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
05
05
2022
revised:
31
08
2022
accepted:
16
09
2022
entrez:
3
2
2023
pubmed:
4
2
2023
medline:
8
2
2023
Statut:
ppublish
Résumé
In 2020, chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death in the United States excluding COVID-19, and its mortality burden has been rising since the 1980s. Smoking cessation, long-term oxygen therapy, noninvasive ventilation, and lung volume reduction surgery have had a beneficial effect on mortality; however, until recently, the effects of pharmacologic therapies on all-cause mortality have been unclear. Inhaled pharmacologic treatments for patients with COPD include combinations of long-acting muscarinic receptor antagonists (LAMAs), long-acting-β
Identifiants
pubmed: 36737119
pii: S0025-6196(22)00542-0
doi: 10.1016/j.mayocp.2022.09.007
pii:
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Bronchodilator Agents
0
Formoterol Fumarate
W34SHF8J2K
Glycopyrrolate
V92SO9WP2I
vilanterol
028LZY775B
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
301-315Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.